Global Molecular Cytogenetics Market 2020: Developments, Challenges, and Forecast Report

[147 Pages Report] The Molecular Cytogenetics Market is projected to reach $2.52 Billion, at a CAGR of 10.1%

The report “Molecular Cytogenetics Market by Product (Kit, Reagent, Probe, Consumable, Software, Service), Technique (In-Situ, FISH, Comparative Genomic Hybridization), Application (Cancer, Genetic), End User (Research Labs, Institutes) – Forecast”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the market along with the estimates and forecasts of the revenue and market share analysis.

Targeted therapies differ from standard chemotherapy in several ways. These therapies act on specific molecular targets associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. The emergence of molecular-based cytogenetic techniques such as fluorescence in situ hybridization is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. The increasing use for molecular cytogenetics in clinical oncology will drive the growth of the global market.

Browse 78 market data tables and 47 figures spread through 147 pages and in-depth TOC – Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224

Market Segmentation in Detailed:

On the basis of techniques, the molecular cytogenetics market is segmented into comparative genomic hybridization, fluorescence in situ hybridization, in situ hybridization, and other techniques.

Based on applications, the market is segmented into genetic disorders, cancer, personalized medicine, and other applications. The genetic disorders segment is expected to account for the largest share of the global market.

Based on end users, the molecular cytogenetics market is segmented into clinical and research laboratories, academic research institutes, pharmaceutical and biotechnology companies, and others. The clinical and research laboratories segment is expected to account for the largest share of the global market. Rise in healthcare expenditure has resulted in the increasing diagnosis of genetic disorder and cancer resulting in increasing use of cytogenetic kits and reagents in the above mentioned end users.

Major Market Developments

• In January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche’s Next Generation Sequencing pipeline.
• In February 2015, Roche acquired Signature Diagnostics AG (Germany).
• In January 2016, Thermo Fisher Scientific, Inc. acquired Affymetrix (U.S.). This acquisition strengthened Thermo Fisher Scientific’s leadership into bioscience business and create new market opportunities in genetic analysis.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224

Based on regions, the global molecular cytogenetics market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as increase in the aging population and increasing prevalence of cancer and genetic disorders in the region.

Key players in the molecular cytogenetics market include F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Gene Technology (U.K.), and Applied Spectral Imaging (U.S.).

High-Resolution Melting Analysis Market expected to grow at a 3.1% CAGR

The report "High Resolution-Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) - Global Forecast", report provides a detailed overview of the major drivers, restraints, and threat impacting the high-resolution melting analysis market along with the estimates and forecasts of the revenue and market share analysis.

The Global High-Resolution Melting Analysis Market is expected to reach $302.1 Million, at a CAGR of 3.1% during the forecast period

Rising prevalence of infectious diseases and genetic disorders; increasing public-private investments, funds, and grants for research on genetic analysis technologies; and advantages of HRM over other genotyping technologies are the major factors driving market growth.

Download PDF (Please provide your specific interest in this report so as to help you better): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216456020

On the basis of product & service:

The Market is segmented into instruments, reagents & consumables, and software & services. The reagents and consumables segment dominated the market in 2016; and is expected to continue to dominate the market during the forecast period. The segment is also expected to grow at the highest CAGR during the forecast period.

On the basis of application:

The High-Resolution Melting Analysis Market is broadly classified into SNP genotyping, mutation scanning, species identification, pathogen identification, epigenetics, and other applications. In 2016, the SNP genotyping segment accounted for the largest share of the Market. This can be attributed to the wide range of applications of SNP genotyping in the diagnosis of genetic and autoimmune diseases, study of the variations in drug responses, drug discovery & development, and the identification of genetic variations in plant or animal genomes.

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=216456020

On the basis of region:

the market is segmented into North America, Europe, Asia-Pacific, and RoW. In 2016, North America (comprising the U.S. and Canada) accounted for the largest share of the global market, followed by Europe. The rising prevalence of infectious diseases, genetic disorders, & other chronic diseases, and the large number of genotyping-based research and development projects are key growth drivers for the HRM market in North America.

Prominent Key Players in High-Resolution Melting Analysis Market:

Thermo Fisher Scientific Inc. (U.S.), F. Hofmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories (U.S.), and QIAGEN N.V. (Netherlands), Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Illumina, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Novacyt (France), Azura Genomics (U.S.), Canon Biomedical (U.S.), and PREMIER Biosoft (U.S.).

Viral Clearance Market 2018 Dynamics Set For Rapid Growth and Trend by 2023

According to the new market research report “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecast”, published by MarketsandMarkets™.

Revenue Growth of the Market:

The Global Viral Clearance Market is expected to reach $724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.

Market Segmentation:-

On the basis of application, the global market is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules.

On the basis of the method, the viral clearance market is segmented into viral removal and viral inactivation. In 2018, the viral removal segment is expected to account for the largest share of the global market due to the growth in the biopharmaceutical R&D activities; the high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research

Download PDF (Please provide your specific interest in this report so as to help you better.): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

Market Growth Drivers:

• Growth in the Pharmaceutical and Biotechnology Industries
• Increasing Number of Drug Launches
• High Incidence and Large Economic Burden of Chronic Diseases
• Possibility of Cell Culture Contamination
• Advancements in Nanofiltration Technology

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

Geographical Analysis:

The North American region is expected to account for the largest share of the market in 2018.

However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

Major Key Players In Global Viral Clearance Market:

Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).

Leukapheresis Market Size 2018, Global Industry Analysis,Share, Trends, Status and Future Forecast 2023

The major factors driving the growth of the Leukapheresis Market include the rising incidence and prevalence of leukemia, growing demand for leukopaks, and the increasing number of blood donations. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes.

The Leukapheresis Products Market is expected to reach USD 27.7 million, at a CAGR of 7.4%

The Leukopaks Market is expected to reach USD 445.6 million, at a CAGR of 46.4% during the forecast period.

Leukapheresis Market Major Drivers;

Increasing incidence and prevalence of leukemia;

Globally, the incidence of leukemia has risen significantly. According to the NIH National Cancer Institute in 2015, 405,815 people were suffering from leukemia in the US. According to NIH estimates, the number of new cases of leukemia has increased on an average rate of 0.3% each year over the last 10 years (from 2006 to 2015). The NIH also estimates that the number of new cases may reach 60,300 in 2018. According to the Leukemia & Lymphoma Society, from 2010 to 2014, leukemia was the sixth-most-common cause of cancer deaths globally.

Browse 134 market data Tables and 49 Figures spread through 194 Pages and in-depth TOC  – Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148

Leukapheresis Market Segmentation:

By product, the apheresis devices segment is expected to account for the largest share of the leukapheresis devices market in 2018

On the basis of type, the leukapheresis devices market is segmented into apheresis devices, leukapheresis columns & cell separators, and leukoreduction filters. In 2017, the apheresis devices segment accounted for the largest share of the leukapheresis devices market. The large share of this segment is attributed to the widespread adoption of apheresis devices for performing therapeutic leukapheresis procedures for the treatment of leukemia and development of leukopaks for clinical and preclinical research.

By product, the mobilized PB leukopaks segment is expected to account for the largest share of the leukopaks market in 2018

On the basis of type, the leuopaks market is segmented into mobilized PB leukopaks, non-mobilized PB leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized PB leukopaks segment is expected to account for the largest share of the global leukopaks market in 2018. The dominant share of this segment is attributed to the increasing demand for low-granulocyte and low-hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=20283148

Asia Pacific is expected to account for the largest share of the leukapheresis market in 2018, followed by North America. The increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the presence of leading pharma and biotech companies focusing on cell therapy research are factors are driving the growth of this regional segment.

The prominent players in the global leukapheresis products market are Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics Corporation (US), Terumo BCT (US), STEMCELL Technologies (Canada), and Macopharma (France).

Some prominent players in the leukopaks market are HemaCare (US), AllCells (US), StemExpress (US), PPA Research Group (US), Key Biologics (US), Caltag Medsystem (UK), ZenBio (US), Precision for Medicine (US), and BioIVT (US).